Intellia Therapeutics Inc... (NTLA)
Intellia Therapeutics Statistics
Share Statistics
Intellia Therapeutics has 103.52M shares outstanding. The number of shares has increased by 7.3% in one year.
| Shares Outstanding | 103.52M |
| Shares Change (YoY) | 7.3% |
| Shares Change (QoQ) | 1.64% |
| Owned by Institutions (%) | 98.29% |
| Shares Floating | 97.42M |
| Failed to Deliver (FTD) Shares | 1.44K |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 24.06M, so 23.62% of the outstanding shares have been sold short.
| Short Interest | 24.06M |
| Short % of Shares Out | 23.62% |
| Short % of Float | 24.13% |
| Short Ratio (days to cover) | 8.36 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -1.95. Intellia Therapeutics's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -1.95 |
| PS Ratio | 19.91 |
| Forward PS | 0.3 |
| PB Ratio | 1.32 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Intellia Therapeutics Inc. has an Enterprise Value (EV) of 2.6B.
| EV / Earnings | -5 |
| EV / Sales | 44.84 |
| EV / EBITDA | -4.95 |
| EV / EBIT | -4.86 |
| EV / FCF | -6.36 |
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of undefined.
| Current Ratio | 5.77 |
| Quick Ratio | 5.77 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | 19.42 |
| Cash Flow / Debt | -1.87 |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is -0.6% and return on capital (ROIC) is -49.37%.
| Return on Equity (ROE) | -0.6% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -49.37% |
| Revenue Per Employee | $143,615.38 |
| Profits Per Employee | $-1,287,893.3 |
| Employee Count | 403 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.84% in the last 52 weeks. The beta is 1.97, so Intellia Therapeutics's price volatility has been higher than the market average.
| Beta | 1.97 |
| 52-Week Price Change | -73.84% |
| 50-Day Moving Average | 9.91 |
| 200-Day Moving Average | 16.87 |
| Relative Strength Index (RSI) | 30.41 |
| Average Volume (20 Days) | 3.26M |
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 57.88M and earned -519.02M in profits. Earnings per share was -5.25.
| Revenue | 57.88M |
| Gross Profit | 57.88M |
| Operating Income | -534.26M |
| Net Income | -519.02M |
| EBITDA | -523.98M |
| EBIT | -534.26M |
| Earnings Per Share (EPS) | -5.25 |
Balance Sheet
The company has 189.18M in cash and 210.2M in debt, giving a net cash position of -21.02M.
| Cash & Cash Equivalents | 189.18M |
| Total Debt | 210.2M |
| Net Cash | -21.02M |
| Retained Earnings | -2.18B |
| Total Assets | 1.19B |
| Working Capital | 529.01M |
Cash Flow
In the last 12 months, operating cash flow was -394.09M and capital expenditures -13.98M, giving a free cash flow of -408.07M.
| Operating Cash Flow | -394.09M |
| Capital Expenditures | -13.98M |
| Free Cash Flow | -408.07M |
| FCF Per Share | -4.13 |
Margins
Gross margin is 100%, with operating and profit margins of -923.1% and -896.77%.
| Gross Margin | 100% |
| Operating Margin | -923.1% |
| Pretax Margin | -896.77% |
| Profit Margin | -896.77% |
| EBITDA Margin | -905.33% |
| EBIT Margin | -923.1% |
| FCF Margin | -705.07% |
Dividends & Yields
NTLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -73.74% |
| FCF Yield | -55.41% |
Analyst Forecast
The average price target for NTLA is $40.5, which is 468.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.5 |
| Price Target Difference | 468.8% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | -1.82 |
| Piotroski F-Score | 2 |